References
Sulocton® [CP 556 S; 1-(4-isopropylthiophenyl)-2-n-octyl-amino-propanol], Continental Pharma S.A., Brussels, Belgium; Continental Pharma, Belgian Patents no739678 (1969) and no755688(1970)
Adriaensen, H.: Current Ther. Research (submitted)
Roba, J.,et al.: Continental Pharma report (to be published)
Roncucci, R.,et al.: ibid. Continental Pharma report
Peeters, H.,et al.: Nature (submitted)
Gillot, P.: unpublished data
Finger, K.F., Page, J.G., Feller, D.R.: Biochem. Pharmacol.15, 1023 (1966)
Blaton, V., Vandamme, D., Peeters, H.: FEBS Letters44, 185 (1974)
Duncombe, W.G.: Biochem. J.83, 6p (1962);88, 7 (1963); Clin. Chim. Acta8, 122 (1964)
Muller, D.W., Allen, D.D.: Soc. Exp. Biol. Med.136 (3), 711 (1971); Andersson, R.,et al.: Atherosclerosis18, 399 (1973); Blackard, W.G., Kokatnur, M.G.: J. Atheroscler. Res.8, 189 (1968)
Dole, V.P.: J. Clin. Invest.,35, 150 (1956)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roncucci, R., Roba, J., Lambelin, G. et al. Potential antilipolytic activity of suloctidil. Naturwissenschaften 62, 141 (1975). https://doi.org/10.1007/BF00623284
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00623284